At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAZE Maze Therapeutics
Market Closed 10-09 16:00:00 EDT
27.11
+1.23
+4.75%
盘后27.11
+0.000.00%
19:30 EDT
High27.19Low25.88Vol670.93K
Open25.88D1 Closing25.88Amplitude5.06%
Mkt Cap1.50BTradable Cap1.01BTotal Shares55.25M
T/O17.99MT/O Rate1.80%Tradable Shares37.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Maze Therapeutics to Present Phase 2 Horizon Data for Mze829 in APOL1-Mediated Kidney Disease at ASN Kidney Week 2026
Reuters  ·  10-07
Maze Therapeutics to Present Phase 2 Horizon Data for Mze829 in APOL1-Mediated Kidney Disease at ASN Kidney Week 2026
Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $202,920.75
Reuters  ·  10-02
Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $202,920.75
Maze Therapeutics Rises After Citi Initiates with 'buy'
Reuters  ·  09-23
Maze Therapeutics Rises After Citi Initiates with 'buy'
Maze Therapeutics initiated with a Buy at Citi
TIPRANKS  ·  09-23
Maze Therapeutics initiated with a Buy at Citi
Maze Therapeutics up over 21%, on Pace for Largest Percent Increase Since September 2025
Dow Jones  ·  09-23
Maze Therapeutics up over 21%, on Pace for Largest Percent Increase Since September 2025
Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Dow Jones  ·  09-23
Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543
Reuters  ·  09-09
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of 9,705 Common Shares for $254,543
Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65
Reuters  ·  09-04
Maze Therapeutics President, R&D and CMO Harold Bernstein Sells 16,141 Common Shares Worth $425,392.65
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
GlobeNewswire  ·  09-02
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75
Reuters  ·  09-01
Maze Therapeutics CSBO Atul Dandekar Disposes of Common Shares Worth $206,823.75
Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update
Dow Jones  ·  08-27
Press Release: MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update
Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement
Reuters  ·  08-18
Maze Therapeutics Director Paula A. Johnson Files Initial Beneficial Ownership Statement
Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors
Reuters  ·  08-18
Maze Therapeutics Names Paula Johnson, Sophie Kornowski to Board of Directors
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares
Reuters  ·  08-15
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of USD 445,522 Common Shares
Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board
Reuters  ·  08-14
Maze Therapeutics Adds Paula Johnson, Sophie Kornowski to Board
Maze Therapeutics Announces Appointments to Its Board of Directors
THOMSON REUTERS  ·  08-14
Maze Therapeutics Announces Appointments to Its Board of Directors
CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge
Reuters  ·  08-14
CAMP4 Therapeutics Q2 Loss Per Share Misses Estimates on Non-Cash Derivative Charge
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
TIPRANKS  ·  08-13
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
Belite Bio Q2 Net Loss Widens on Higher Expenses
Reuters  ·  08-13
Belite Bio Q2 Net Loss Widens on Higher Expenses
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
TIPRANKS  ·  08-12
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

Introduction

Company Name.
Maze Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--